Evaluation of the efficacy and safety of bromocriptine QR in type 2 diabetes

Abstract

Context:Diabetes mellitus is a chronic metabolic disorder of endocrinal origin with multiorgan involement. Today's physician has a lot many options to choose for treating type 2 diabetes, but does not always manages to achieve optimal glycemic control. The newer drug bromocriptine acts by novel hypothalamic circadian rhythm resetting mechanism.Objective:To evaluate the efficacy and safety of bromocriptine QR in type 2 diabetes.Materials and Methods:105 patients according to inclusion and exclusion criteria were randomized into three groups by simple randomization. Group 1 received bromocriprine 2.4 mg once daily, group 2 received metformin 500 mg twice daily while group 3 received bromocriprine 1.6 mg daily and metformin 500 mg twice daily. Baseline measurement of fasting and postprandial blood sugar, HbA1C and BMI were followed up at 6th and 12th weeks. Safety evaluation was done by questioning the patient and also through routine hematological and biochemical parameters. Z test was used for analysis.Results:Group 1 showed significant reduction in fasting and postprandial sugar and HbA1c at 12 weeks. While groups 2 and 3 showed even higher reduction in these parameters albeit with slightly more adverse drug events like nausea, vomiting compared to group 1.Conclusion:Bromocriptine QR is an effective and safe antidiabetic drug which can be employed as monotherapy or in conjuction with metformin to achieve and maintain optimal glycemic control.

Study to assess the role of bromocriptine in treatment of diabetes mellitus

“…This finding was comparable to study conducted by Ramteke, et al and this may be attributed to the complex central action of bromocriptine through neural circuits and related to its effects on regulation of hypothalamic circadian rhythm. 33 Bromocriptine is relatively safe and it meets all the USFDA cardiovascular safety guidelines, use results in 40% reduction in cardiovascular end points. 23 It had also benefitted remarkably the patients of type 2 diabetes mellitus with dyslipidemia, obese patients, depressed patients with limited mobility and patient with profound insulin resistance.…”

Brain Signaling Systems in the Type 2 Diabetes and Metabolic Syndrome: Promising Target to Treat and Prevent These Diseases

“…When co-administered, BC caused the increase of hypoglycemic effect of low-dose insulin and enhanced the glucose-lowering effect of metformin, glipizide and pioglitazone, as demonstrated in clinical trials [211,222,227,228] and in animal models of MS [224,225]. The treatment of patients with T2DM with a combination of metformin (1000 mg/day) and BC (0.8–1.6 mg/day) induced a more pronounced decrease of the levels of fasting and postprandial glucose and glycated hemoglobin than in the monotherapy [228].…”

“…The treatment of patients with T2DM with a combination of metformin (1000 mg/day) and BC (0.8–1.6 mg/day) induced a more pronounced decrease of the levels of fasting and postprandial glucose and glycated hemoglobin than in the monotherapy [228]. Co-administration of BC and metformin to patients with T2DM enhanced the glucose-lowering effect of these drugs, reduced their effective doses and allowed avoiding the side effects [227]. The potentiation of glucose-lowering effect of co-administered BC and glipizide was shown in rats with alloxan T1DM [225].…”

A review of the efficacy and safety of oral antidiabetic drugs

“…In a small study of 105 patients with type 2 diabetes (mean HbA 1c of 7.8%), subjects were randomized to receive bromocriptine monotherapy, dual bromocriptine and metformin or metformin monotherapy over 12 weeks [141]. Metformin monotherapy was superior to bromocriptine monotherapy in reduction of HbA 1c and FPG.…”